Morphine Syrup Dosage for Severe Pain Management
For severe pain management, oral morphine syrup should be initiated at 20-40 mg every 4 hours with rescue doses of 10-15% of the total daily dose available hourly for breakthrough pain. 1, 2, 3
Initial Dosing and Titration
- Oral morphine is the first-line strong opioid for moderate to severe cancer pain due to its effectiveness, tolerability, simplicity of administration, and cost-effectiveness 2
- For opioid-naïve patients with severe pain, start with:
- For patients with urgent severe pain requiring immediate relief, intravenous administration is preferred:
Dose Conversion and Adjustments
- When converting between routes:
- Titration process:
Maintenance Therapy
- After titration, the total daily dose can be calculated and converted to a modified-release formulation 5
- Continue to provide immediate-release morphine syrup for breakthrough pain at 10-15% of the total daily dose 5, 2
- No upper limit exists for morphine dosing; the appropriate dose is one that provides adequate analgesia with acceptable side effects 2, 3
- Most patients with cancer pain achieve adequate relief with doses between 100-250 mg daily, though doses can range from 25-2000 mg 6
Management of Side Effects
- Common adverse effects include:
- For intolerable side effects:
Special Considerations
- In renal impairment, use reduced doses and frequency 2
- For patients unable to take oral medication, consider subcutaneous route as first alternative 5
- Monitor closely for respiratory depression, especially within the first 24-72 hours of initiating therapy 3
- Be vigilant for signs of neuroexcitatory side effects (myoclonus, seizures) which may occur with high doses or accumulation of metabolites 7
Common Pitfalls to Avoid
- Inadequate breakthrough dosing (should be 10-15% of total daily dose) 4, 2
- Insufficient dose titration leading to uncontrolled pain 3
- Failure to prophylactically manage constipation 2
- Abandoning morphine too quickly due to side effects rather than managing them appropriately 2
- Excessive sedation when converting from immediate-release to extended-release formulations without dose adjustment 3